Compare DexCom, Inc. (DXCM) vs Slide Insurance Holdings Inc. Common Stock (SLDE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Slide Insurance Holdings Inc. Common Stock — how do they compare? DexCom, Inc. trades at $84.41 (market cap $32.09B), while Slide Insurance Holdings Inc. Common Stock trades at $25.59 (market cap $2.98B). The key difference: DexCom, Inc. is far larger — about 10.8× Slide Insurance Holdings Inc. Common Stock's market cap, and Slide Insurance Holdings Inc. Common Stock pays a 1.1% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Slide Insurance Holdings Inc. Common Stock for 0 Days on average.
| DXCM | SLDE | |
|---|---|---|
Market Cap | $32.09B | $2.98B |
Volume | 3,819,730 | 927,183 |
Sector | Health | Financials |
52-Week High | $92.34 | $26.48 |
52-Week Low | $54.84 | $14.38 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.54B | $1.78B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $83.47, down 2.85% on the day, amid a generally bullish technical and fundamental backdrop. The stock shows strong revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million, and has consistently beaten earnings expectations. Analyst consensus is strongly positive with a price target of $96.14, and recent news highlights expansion opportunities in the Type 2 diabetes CGM market.
The outlook for DXCM is positive, driven by solid financial performance and market expansion potential. Key opportunities include growing adoption of its CGM systems, while risks involve competitive pressures and reimbursement challenges. The stock presents a compelling case for growth-oriented investors, supported by strong analyst backing and institutional interest.
SLDE trades at $25.50, down slightly (-0.12%) on the day, with strong fundamental metrics including a P/E of 6.16 and net income margin of 40.02%. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results scheduled for October 27, 2026. Revenue growth from $1.16B in 2025 to projected $1.4B in 2026 demonstrates solid business momentum, supported by expanded insurance offerings in key markets.
The stock presents attractive value with strong profitability and analyst support (80% buy ratings), though hurricane exposure in Florida remains a key risk. Current price sits near consensus target of $25.00, suggesting limited near-term upside but solid fundamentals for long-term investors. Management's share repurchase program and dividend initiation provide additional shareholder value support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Slide Insurance Holdings Inc. Common Stock
Slide Insurance Holdings, Inc. is a technology-enabled insurance company based in Florida that underwrites coastal specialty personal lines insurance, including homeowners and condominium unit owner policies, and also provides reinsurance and insurance agency services.
Read more on SLDE →
